Table 3.
Adverse events during consolidation treatment, n (%).
| Total N = 175 |
ATO N = 85 |
RIF N = 90 |
p | |
|---|---|---|---|---|
| Infection/FUO | 60 (34.3) | 36 (42.4) | 24 (26.7) | 0.029 |
| PCT | 48 (27.4) | 29 (34.1) | 19 (21.1) | 0.063 |
| Coagulopathy events | ||||
| Hemorrhage | 7 (4.0) | 5 (5.9) | 2 (2.2) | 0.267 |
| Thrombosis | 2 (1.1) | 1 (1.2) | 1 (1.1) | 1.000 |
| Liver | ||||
| Grade 1–2 | 5 (2.9) | 2 (2.4) | 3 (3.3) | 1.000 |
| Grade 3–4 | 0 (0) | 0 (0) | 0 (0) | - |
| Cardiaca | ||||
| Grade 1–2 | 3 (1.7) | 3 (3.5) | 0 (0) | 0.112 |
| Grade 3–4 | 1 (0.6) | 1 (1.2) | 0 (0) | 0.486 |
| Gastrointestinal dysfunction | ||||
| Grade 1–2 | 27 (15.4) | 11 (12.9) | 16 (17.8) | 0.376 |
| Grade 3–4 | 0 (0) | 0 (0) | 0 (0) | - |
| Rash | 2 (1.1) | 1 (1.2) | 1 (3.3) | 1.000 |
FUO fever of unknown origin, PCT pseudotumor cerebri.
aThe difference in the total incidence of cardiac events (grade 1–4) between the ATO and RIF groups was close to being significant (p = 0.054).